iBio
IBIO
50 hedge funds and large institutions have $31.6M invested in iBio in 2025 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 8 closing their positions.
968% more capital invested
Capital invested by funds: $2.96M → $31.6M (+$28.6M)
300% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 3
225% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 8
56% more funds holding
Funds holding: 32 → 50 (+18)
54.5% more ownership
Funds ownership: 18.16% → 72.66% (+54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.04M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$2.81M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$2.73M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$2.67M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$874K |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$310K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$109K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$37.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$36.8K |
IBIO Hedge Fund Activity: Q4 2025 in Review
50 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q4 2025, worth a combined $31.6M — up 968% from $2.96M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new IBIO positions and 8 closed out — a net gain of 18 holders — while 12 added to existing stakes and 3 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $3.04M. The largest seller was Lynx1 Capital Management, exiting entirely with an estimated $874K sold.
- 50 institutional investors held iBio (IBIO) as of Q4 2025, up from 32 in Q3 2025.
- Funds reported $31.6M of iBio stock for Q4 2025, up 968% quarter-over-quarter.
- 26 funds opened new iBio positions in Q4 2025 and 8 closed out, a net change of +18 holders.
- The largest iBio buyer in Q4 2025 was EcoR1 Capital, an estimated $3.04M added.
- The largest iBio seller in Q4 2025 was Lynx1 Capital Management, an estimated $874K sold.
Based on aggregated 13F filings for Q4 2025.